CASI Pharmaceuticals Inc Cash Flow Conversion Efficiency
CASI Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, CASI Pharmaceuticals Inc (CASI) has a cash flow conversion efficiency ratio of -0.014x as of March 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-843.00K) by net assets ($62.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CASI Pharmaceuticals Inc (1994–2024)
Cash flow conversion efficiency of CASI Pharmaceuticals Inc from 1994 to 2024. This chart illustrates how CASI Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CASI Pharmaceuticals Inc share price for real-time trading data and today's change.
CASI Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
CASI Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CASI Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CASI Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see CASI Pharmaceuticals Inc (CASI) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bang Overseas Limited
NSE:BANG
|
-0.049x |
|
Invibes Advertising NV
PA:ALINV
|
-0.215x |
|
Corazon Mining Ltd
AU:CZN
|
-0.019x |
|
Brüder Mannesmann Aktiengesellschaft
F:BMM
|
-0.171x |
|
FIXEDzone as
PR:FIXED
|
N/A |
|
Sego Resources Inc
V:SGZ
|
-0.015x |
|
Alliance Pharma plc
LSE:APH
|
0.099x |
|
Taiton Resources Ltd
AU:T88
|
-0.020x |
Annual Cash Flow Conversion Efficiency for CASI Pharmaceuticals Inc (1994–2024)
The table below shows the annual cash flow conversion efficiency of CASI Pharmaceuticals Inc from 1994 to 2024. Review CASI FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.85 Million | $-29.22 Million | -15.788x | -1810.76% |
| 2023-12-31 | $24.16 Million | $-19.97 Million | -0.826x | -162.26% |
| 2022-12-31 | $66.93 Million | $-21.09 Million | -0.315x | -26.72% |
| 2021-12-31 | $107.96 Million | $-26.84 Million | -0.249x | +0.52% |
| 2020-12-31 | $103.57 Million | $-25.89 Million | -0.250x | -0.72% |
| 2019-12-31 | $93.67 Million | $-23.24 Million | -0.248x | +4.97% |
| 2018-12-31 | $109.46 Million | $-28.58 Million | -0.261x | -57.19% |
| 2017-12-31 | $38.54 Million | $-6.40 Million | -0.166x | +42.68% |
| 2016-12-31 | $20.78 Million | $-6.02 Million | -0.290x | -132.00% |
| 2015-12-31 | $-6.09 Million | $-5.51 Million | 0.906x | -90.43% |
| 2014-12-31 | $-422.21K | $-4.00 Million | 9.463x | +4416.67% |
| 2013-12-31 | $14.94 Million | $-3.28 Million | -0.219x | +18.39% |
| 2012-12-31 | $8.24 Million | $-2.21 Million | -0.269x | +84.08% |
| 2011-12-31 | $2.53 Million | $-4.27 Million | -1.687x | -81.46% |
| 2010-12-31 | $5.33 Million | $-4.96 Million | -0.930x | -117.54% |
| 2009-12-31 | $-1.93 Million | $-10.21 Million | 5.303x | +251.61% |
| 2008-12-31 | $5.92 Million | $-20.71 Million | -3.498x | -299.91% |
| 2007-12-31 | $26.90 Million | $-23.52 Million | -0.875x | -97.78% |
| 2006-12-31 | $46.98 Million | $-20.77 Million | -0.442x | +10.49% |
| 2005-12-31 | $29.39 Million | $-14.52 Million | -0.494x | -7.57% |
| 2004-12-31 | $35.72 Million | $-16.41 Million | -0.459x | +33.95% |
| 2003-12-31 | $34.88 Million | $-24.25 Million | -0.695x | +83.95% |
| 2002-12-31 | $10.51 Million | $-45.53 Million | -4.332x | -90.19% |
| 2001-12-31 | $23.21 Million | $-52.87 Million | -2.278x | +1.89% |
| 2000-12-31 | $19.06 Million | $-44.25 Million | -2.322x | -42.68% |
| 1999-12-31 | $22.00 Million | $-35.80 Million | -1.627x | -332.20% |
| 1998-12-31 | $33.20 Million | $-12.50 Million | -0.377x | -140.17% |
| 1997-12-31 | $42.10 Million | $-6.60 Million | -0.157x | -239.90% |
| 1996-12-31 | $47.70 Million | $-2.20 Million | -0.046x | +96.26% |
| 1995-12-31 | $3.60 Million | $-4.44 Million | -1.233x | +94.33% |
| 1994-12-31 | $200.00K | $-4.35 Million | -21.750x | -- |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more